Publications

5898 Results

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial

Authors
Shadman M;LeBlanc M;Rimsza L;Leonard JP;Smith SM;Li H;Friedberg JW
Journal / Conference
JAMA Oncology. 2026 Feb 26; e260042. DOI: 10.1001/jamaoncol.2026.0042. Online ahead of print
Year
2026
Research Committee(s)
Lymphoma
PMID
PMID41746629
Study Number(s)
S0016

Long-term follow-up of S0221, comparing alternative dose schedules of anthracycline/taxane therapy in early breast cancer

Authors
Ali A;Barlow WE;Moore HC;Hobday TJ;Isaacs C;Salim M;Albain KS;Chew HK;Burton GV;Srkalovic G;McGregor BA;Flaherty LE;Lew DL;Gralow JR;Hortobagyi GN;Sharma P;Pusztai L;Budd GT
Journal / Conference
JNCI Cancer Spectrum. 2026 Mar 14; pkag024. DOI: 10.1093/jncics/pkag024. Online ahead of print
Year
2026
Research Committee(s)
Breast
PMID
PMID41832961
Study Number(s)
S0221

Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)

Authors
Chae YK;Othus M;Lyu J;Lee S;Paik S;Dietrich E;Jung CM;Chung LI;Patel S;Kurzrock R
Journal / Conference
Journal for ImmunoTherapy of Cancer. 2026 Mar 11; 14: e013260. DOI: 10.1136/jitc-2025-013260.
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41819545
Study Number(s)
S1609

DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers

Authors
Patel SP;Othus M;Chae YK;Azenkot T;Alviz C;Threlkel S;Haymaker C;Streicher HZ;Magner CM;Chen HX;Sharon E;Ryan CW;Blanke CD;Kurzrock R
Journal / Conference
Annals of Oncology. 2026 Apr 15; S0923-7534(26)00142-0. DOI: 10.1016/j.annonc.2026.04.004. Epub ahead of print
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41997295
Study Number(s)
S1609

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results

Authors
Chae YK
Journal / Conference
Journal of Gynecologic Oncology. 2026 Mar 25; e92. DOI: 10.3802/jgo.2026.37.e92. Epub ahead of print
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41995270
Study Number(s)
S1609

Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)

Authors
Swiecicki PL;Othus M;Patel SP;Chae YK;Kurzrock R
Journal / Conference
Cancer. 2026 Apr 1; e70374. DOI: 10.1002/cncr.70374.
Year
2026
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID41892875
Study Number(s)
S1609

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1

Authors
Campbell KM;Chen DG;Bustami ZE;Al Deen NN;Medina E;Gonzalez CR;Maxey J;Thompson MA;Samorodnitsky S;Kuklinski LF;Perez Garcilazo I;Baselga-Carretero I;Vega-Crespo A;Chen JM;Elumalai R;Visitacion M;Schiemann R;Padron L;Chang C;Zelin AE;Chelluri SS;Boffo S;Kendra KL;Chmielowski B;Truong TG;Khushalani NI;Collichio F;Ikeguchi AP;Victor AI;Margolin KA;Johnson DB;Chen Y;Sosman JA;Patel SP;Hu-Lieskovan S;Moon J;Wells DK;Bellasea S;Vanderwalde AM;Wu MC;Scumpia PO;Ribas A
Journal / Conference
Cancer Discovery. 2026 Apr 21; . DOI: 10.1158/2159-8290.CD-25-1745.
Year
2026
Research Committee(s)
Melanoma
Study Number(s)
S1616

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826

Authors
Castellino SM;Li H;Herrera AF;LeBlanc ML;Parsons SK;Unger JM;Punnett A;Hodgson D;Keller FG;Drachtman RA;Lamble A;Forlenza CJ;Doan A;Rutherford SC;Evens AM;Little RF;Smith MA;Hoppe BS;Song JY;Smith SM;Friedberg JW;Kelly KM
Journal / Conference
Journal of Clinical Oncology. 2026 Jan 9; JCO2500203. DOI: 10.1200/JCO-25-00203.
Year
2026
Research Committee(s)
Lymphoma
PMID
PMID41512237
PMC
13192332
Study Number(s)
S1826

Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model

Authors
Vertosick EA;Goodman P;Tangen CM;Till C;Thompson IM;Lucia MS;Eastham J;Lilja H;Vickers AJ
Journal / Conference
European Urology Focus. 2026 Mar 20; S2405-4569(26)00038-6. DOI: 10.1016/j.euf.2026.03.005. Online ahead of print
Year
2026
Research Committee(s)
Cancer Control
PMID
PMID41864782
Study Number(s)
SWOG-9217

Indian Hedgehog expression and association with cetuximab benefit in metastatic colorectal cancer (mCRC): Evidence from CALGB (Alliance)/SWOG 80405.

Authors
Bartolini M;Yang Y;Millstein J;Ou FS;Soni S;Battaglin F;Mittal P;Algaze S;Shah UH;Torres-Gonzalez L;Zhang W;Venook AP;Innocenti F;Puccini A;Lenz HJ
Journal / Conference
ASCO GI Cancers Symposium (January 8-10, 2026, San Francisco, CA); Poster; Abstract #198
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405